Protagonist Therapeutics, Inc. (PTGX)
After hours:
Chart Events
Performance Outlook
| Previous Close | 8.25 |
| Open | 8.36 |
| Bid | 7.50 x 800 |
| Ask | 8.44 x 800 |
| Day's Range | 8.28 - 8.78 |
| 52 Week Range | 6.91 - 38.11 |
| Volume | |
| Avg. Volume | 957,457 |
| Market Cap | 413.779M |
| Beta (5Y Monthly) | 2.55 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.58 |
| Earnings Date | Nov 01, 2022 - Nov 07, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 36.00 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for PTGX
Related Research
- Protagonist Therapeutics, Inc.Analyst Report: Bristol-Myers Squibb CompanyBristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.RatingFair ValueEconomic Moat13 days agoMorningstar
- Zacks
Protagonist Therapeutics (PTGX) Upgraded to Buy: What Does It Mean for the Stock?
Protagonist Therapeutics (PTGX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- PR Newswire
Protagonist Therapeutics Reports Granting of Inducement Award
Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported that on September 15, 2022, it issued an inducement award to Pedro Oyuela, M.D., the Company's recently hired Vice President of Pharmacovigilance, in accordance with the terms of Dr. Oyuela's employment offer letter. The award was granted under the Protagonist Therapeutics Amended and Restated Inducement Plan, which was adopted May 29, 2018, and amended February 18, 2020 and February 15, 2022.
- Zacks
How Much Upside is Left in Protagonist Therapeutics (PTGX)? Wall Street Analysts Think 302%
The consensus price target hints at a 301.5% upside potential for Protagonist Therapeutics (PTGX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
